

amount of biologically active chemokine.

6. (Amended) A method of producing a substantial amount of biologically active chemokine which comprises inserting at least one chemokine gene into a Sendai virus vector, allowing the vector to produce said chemokine, and recovering said chemokine.

9. (Amended) A method of treating human immunodeficiency virus infection, which comprises administering to human subjects a recombinant Sendai virus vector expressing a substantial amount of biologically active CXC-chemokine and allowing the vector to express the chemokine *in vivo*.

10. (Amended) A method of treating human immunodeficiency virus infection, which comprises collecting target cells from human subjects, infecting the cells with a recombinant Sendai virus vector expressing a substantial amount of biologically active CXC-chemokine, and giving the infected cells back to the human subjects.

11. (Amended) A pharmaceutical composition comprising a recombinant Sendai virus vector expressing a substantial amount of biologically active stromal cell-derived factor  $\alpha$  or stromal cell-derived factor  $\beta$  and a pharmaceutically acceptable

carrier, wherein said vector is disseminative.

12. (Amended) A pharmaceutical composition comprising a recombinant Sendai virus vector expressing a substantial amount of biologically active stromal cell-derived factor  $\alpha$  or stromal cell-derived factor  $\beta$  and a pharmaceutically acceptable carrier, wherein said vector is infectious and replicates autonomously, but is not disseminative.

14. (Amended) A host cell transfected with a recombinant Sendai virus vector expressing a substantial amount of biologically active chemokine.

15. (Amended) A method of inhibiting HIV proliferation which comprises, incubating the host cell of claim 14 in vitro to allow [chemokine] secretion of a substantial amount of biologically active chemokine; and contacting said chemokine with cells that are infected with HIV.

#### Support for the Amendments

Claims 1, 6, 9, 10, 11, 12, 13 14, and 15 have been amended to require a "substantial amount of biologically active" chemokine. Support for these amendments can be found in the specification in Example 2, pages 10-11 which states that "substantial